Here are the S-3 shelf registrations from Ensysce Bioscience WTS (ENSCW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow ENSCW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENSCW filings page.
Ensysce Biosciences, Inc. proposes the registration and resale of up to 1,300,000 shares of common stock, consisting largely of shares issuable to a manufacturing counterparty and shares issuable under a separate agreement. The prospectus states the Selling Securityholders will receive all proceeds; the company will pay registration costs.
The company reported 15,365,530 shares outstanding as of June 2, 2026 and disclosed recent financing arrangements that include convertible preferred stock and multiple warrant series. The prospectus notes Nasdaq compliance risks, including a May 21, 2026 notice related to a $2.5 million stockholders’ equity requirement and a bid-price noncompliance notice with a compliance deadline of August 24, 2026. The preliminary prospectus is subject to completion.